Clinical trials: Recurrent Head and Neck Carcinoma
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Carcinoma, Squamous Cell of Head and Neck
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
The trial is designed as a multi-center, open label Phase 2 trial that investigates the efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT01417936
- Testing
- Sym004
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 26 people
- Sponsor
- Symphogen A/S
First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Conditions
- First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel, Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Trial name
- XP versus XT (NCT00816634)
- Testing
- Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Samsung Medical Center
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent)…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04754321
- Testing
- External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
The combination of cisplatin and irinotecan has significant anti-tumor activity in esophageal cancer. Oxaliplatin has been shown to have activity in combination with 5-Fluorouracil (5FU) and radiation in treatment of locally…
- Trial name
- NCT00256269
- Testing
- Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Irvine
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of recombinant interleukin-12 when given together with cetuximab and to see how well they work in treating patients with squamous cell carcinoma of the head and neck…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT01468896
- Testing
- Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors
The PRINCESS study is a hypothesis-generating, interventional, open-label, non pharmacological trial designed to characterize the translational and clinical implications of the regular assumptions of inulin on Gut Microbiota…
- Trial name
- PRINCESS (NCT05821751)
- Testing
- inulin, Pembrolizumab, Nivolumab
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
- Trial name
- NCT03799744
- Testing
- VCN-01, Durvalumab
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Institut Català d'Oncologia
Nasopharyngeal Carcinoma
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant…
- Trial name
- NCT03130270
- Testing
- Apatinib mesylate tablet
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Guilin Medical University, China
Nasopharyngeal Carcinoma
Endostar for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to determine whether endostar and IMRT is effective in the treatment of locally recurrent nasopharyngeal carcinoma patients compared with IMRT alone.
- Trial name
- NCT02636231
- Testing
- Endostatins, IMRT
- Where
- 8 sites in China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05898256
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Guangxi Medical University
Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back.
- Trial name
- NCT03727061
- Testing
- Nivolumab, Porfimer Sodium, Interstitial Illumination Photodynamic Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent and/or Metastatic Platinum-refractory SCCHN
Nivolumab in Recurrent and/or Metastatic SCCHN
Recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) are a common clinical situation and although this group of patients has very heterogeneous disease characteristics, they share a dismal prognosis…
- Trial name
- TopNIVO (NCT03226756)
- Testing
- Nivolumab Injection
- Where
- 18 sites in France
- Volunteers
- 351 people
- Sponsor
- UNICANCER
Head and Neck Cancer, Pain
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer
RATIONALE: Acupuncture may help relieve pain and dysfunction caused by cancer surgery. It is not yet known whether acupuncture is more effective than standard therapy in treating pain and dysfunction in patients who have…
- Trial name
- NCT00090337
- Testing
- acupuncture therapy, standard follow-up care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma
- Trial name
- NCT04146402
- Testing
- SCT-I10A+chemo
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Recurrent Head and Neck Squamous Cell Carcinoma
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases.
- Trial name
- ECLIPSE (NCT06699212)
- Testing
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 412 people
- Sponsor
- Rakuten Medical, Inc.
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
HNSCC
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the…
- Trial name
- NCT04997902
- Testing
- Tipifarnib, Alpelisib
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Kura Oncology, Inc.
Squamous Cell Carcinoma of the Head and Neck
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called…
- Trial name
- NCT02350712
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.